
Rasem Mourad
Examiner (ID: 7274, Phone: (571)270-7770 , Office: P/2836 )
| Most Active Art Unit | 2836 |
| Art Unit(s) | 2836 |
| Total Applications | 617 |
| Issued Applications | 444 |
| Pending Applications | 46 |
| Abandoned Applications | 142 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11403043
[patent_doc_number] => 20170023577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-26
[patent_title] => 'METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY'
[patent_app_type] => utility
[patent_app_number] => 15/080709
[patent_app_country] => US
[patent_app_date] => 2016-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56764
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080709
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/080709 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY | Mar 24, 2016 | Abandoned |
Array
(
[id] => 11090730
[patent_doc_number] => 20160287699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-10-06
[patent_title] => 'FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/079136
[patent_app_country] => US
[patent_app_date] => 2016-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 9847
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079136
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/079136 | FGFR/PD-1 combination therapy for the treatment of cancer | Mar 23, 2016 | Issued |
Array
(
[id] => 16954895
[patent_doc_number] => 11058722
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
[patent_app_type] => utility
[patent_app_number] => 15/560558
[patent_app_country] => US
[patent_app_date] => 2016-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 13280
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/560558 | Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain | Mar 21, 2016 | Issued |
Array
(
[id] => 16954895
[patent_doc_number] => 11058722
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
[patent_app_type] => utility
[patent_app_number] => 15/560558
[patent_app_country] => US
[patent_app_date] => 2016-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 13280
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/560558 | Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain | Mar 21, 2016 | Issued |
Array
(
[id] => 17586580
[patent_doc_number] => 11324822
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 15/559402
[patent_app_country] => US
[patent_app_date] => 2016-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12023
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559402
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/559402 | Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer | Mar 17, 2016 | Issued |
Array
(
[id] => 12185493
[patent_doc_number] => 20180044429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-15
[patent_title] => 'CD27 AGONISTS'
[patent_app_type] => utility
[patent_app_number] => 15/557035
[patent_app_country] => US
[patent_app_date] => 2016-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 27358
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15557035
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/557035 | CD27 AGONISTS | Mar 8, 2016 | Abandoned |
Array
(
[id] => 11948284
[patent_doc_number] => 20170252435
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-07
[patent_title] => 'Combination'
[patent_app_type] => utility
[patent_app_number] => 15/060071
[patent_app_country] => US
[patent_app_date] => 2016-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 15107
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15060071
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/060071 | Combination | Mar 2, 2016 | Abandoned |
| 15/058286 | ADOPTIVE T-CELL THERAPY USING FceRI-BASED CHIMERIC ANTIGEN RECEPTORS FOR TREATING IgE-MEDIATED ALLERGIC DISEASES | Mar 1, 2016 | Abandoned |
Array
(
[id] => 13793361
[patent_doc_number] => 20190010219
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
[patent_app_type] => utility
[patent_app_number] => 15/753872
[patent_app_country] => US
[patent_app_date] => 2016-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753872
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/753872 | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells | Feb 23, 2016 | Abandoned |
Array
(
[id] => 10822106
[patent_doc_number] => 20160168270
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-16
[patent_title] => 'PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID'
[patent_app_type] => utility
[patent_app_number] => 15/047612
[patent_app_country] => US
[patent_app_date] => 2016-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 28219
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15047612
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/047612 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | Feb 17, 2016 | Abandoned |
Array
(
[id] => 16605980
[patent_doc_number] => 10906972
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-02
[patent_title] => Cancer cell specific anti-podocalyxin antibody and method for producing same
[patent_app_type] => utility
[patent_app_number] => 15/549923
[patent_app_country] => US
[patent_app_date] => 2016-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 15391
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549923
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/549923 | Cancer cell specific anti-podocalyxin antibody and method for producing same | Feb 11, 2016 | Issued |
Array
(
[id] => 10813744
[patent_doc_number] => 20160159904
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'CANCER STEM CELL-SPECIFIC MOLECULE'
[patent_app_type] => utility
[patent_app_number] => 15/042548
[patent_app_country] => US
[patent_app_date] => 2016-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 74
[patent_figures_cnt] => 74
[patent_no_of_words] => 44171
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15042548
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/042548 | Cancer stem cell-specific molecule | Feb 11, 2016 | Issued |
Array
(
[id] => 18604709
[patent_doc_number] => 11746159
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Humanized anti-MUC1* antibodies
[patent_app_type] => utility
[patent_app_number] => 15/549942
[patent_app_country] => US
[patent_app_date] => 2016-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 62
[patent_no_of_words] => 33722
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549942
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/549942 | Humanized anti-MUC1* antibodies | Feb 9, 2016 | Issued |
Array
(
[id] => 15696805
[patent_doc_number] => 10604570
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-31
[patent_title] => Chimeric antigen receptor signalling system comprising heterodimerization domains
[patent_app_type] => utility
[patent_app_number] => 15/548340
[patent_app_country] => US
[patent_app_date] => 2016-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 13
[patent_no_of_words] => 10151
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15548340
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/548340 | Chimeric antigen receptor signalling system comprising heterodimerization domains | Feb 3, 2016 | Issued |
Array
(
[id] => 12185488
[patent_doc_number] => 20180044424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-15
[patent_title] => 'CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/548202
[patent_app_country] => US
[patent_app_date] => 2016-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 62
[patent_no_of_words] => 114282
[patent_no_of_claims] => 95
[patent_no_of_ind_claims] => 43
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15548202
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/548202 | Car-expressing cells against multiple tumor antigens and uses thereof | Jan 31, 2016 | Issued |
Array
(
[id] => 13748791
[patent_doc_number] => 10167326
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-01-01
[patent_title] => Alpha-fetoprotein "ring and tail" peptides
[patent_app_type] => utility
[patent_app_number] => 15/010724
[patent_app_country] => US
[patent_app_date] => 2016-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 12753
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15010724
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/010724 | Alpha-fetoprotein "ring and tail" peptides | Jan 28, 2016 | Issued |
Array
(
[id] => 12149990
[patent_doc_number] => 20180021253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY'
[patent_app_type] => utility
[patent_app_number] => 15/546852
[patent_app_country] => US
[patent_app_date] => 2016-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 22301
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 23
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546852
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/546852 | Peritumoral and intratumoral materials for cancer therapy | Jan 28, 2016 | Issued |
Array
(
[id] => 10782952
[patent_doc_number] => 20160129109
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-05-12
[patent_title] => 'UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER'
[patent_app_type] => utility
[patent_app_number] => 14/990514
[patent_app_country] => US
[patent_app_date] => 2016-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10490
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14990514
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/990514 | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer | Jan 6, 2016 | Issued |
Array
(
[id] => 11066241
[patent_doc_number] => 20160263203
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-15
[patent_title] => 'Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase'
[patent_app_type] => utility
[patent_app_number] => 14/984959
[patent_app_country] => US
[patent_app_date] => 2015-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 103
[patent_figures_cnt] => 103
[patent_no_of_words] => 102982
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14984959
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/984959 | Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase | Dec 29, 2015 | Abandoned |
Array
(
[id] => 11928682
[patent_doc_number] => 09795660
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-10-24
[patent_title] => 'Id-protein targeted tumor cell vaccine'
[patent_app_type] => utility
[patent_app_number] => 14/981114
[patent_app_country] => US
[patent_app_date] => 2015-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 63
[patent_no_of_words] => 15152
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14981114
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/981114 | Id-protein targeted tumor cell vaccine | Dec 27, 2015 | Issued |